In vivo and in vitro characterization of [18F]-FE-(+)-DTBZ as a tracer for beta-cell mass

Nuclear Medicine and Biology

Volumn 37, Issue 3, 2010, Pages 357-363

  Eriksson, Olof ^a   Jahan, Mahabuba ^b   Johnström, Peter ^b,c   Korsgren, Olle ^a   Sundin, Anders ^a,b   Halldin, Christer ^b   Johansson, Lars ^a,d  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c ASTRAZENECA R AND D   (Sweden)

^d ASTRAZENECA R AND D   (Sweden)

Author keywords

Beta cell mass; DTBZ; Positron emission tomography; VMAT2

Indexed keywords

9 FLUOROETHYL DIHYDROTETRABENAZINE F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; AUTORADIOGRAPHY; BINDING KINETICS; BONE TISSUE; CELL SIZE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG UPTAKE; ENDOCRINE GLAND; EXOCRINE GLAND; HEPATOBILIARY SYSTEM; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; ISOTOPE TRACING; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; POSITRON EMISSION TOMOGRAPHY;

ANIMALS; CELL COUNT; CELLS, CULTURED; HUMANS; INSULIN-SECRETING CELLS; METABOLIC CLEARANCE RATE; ORGAN SPECIFICITY; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SWINE; TETRABENAZINE; TISSUE DISTRIBUTION;

EID: 77950300183     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2009.12.004     Document Type: Article

References (13)

1. Kahn S.E., Carr D.B., Faulenbach M.V., Utzschneider K.M. An examination of beta-cell function measures and their potential use for estimating beta-cell mass. Diabetes Obes Metab 2008, 10(Suppl 4):63-76. [Review].
2. Sweet I.R., Cook D.L., Lernmark A., Greenbaum C.J., Krohn K.A. Non-invasive imaging of beta cell mass: a quantitative analysis. Diabetes Technol Ther 2004, 6(5):652-659.
3. 11C]tetrabenazine, a vesicular monoamine uptake inhibitor, for PET imaging studies. Appl Radiat Isot 1993, 44(4):673-676.
4. Anlauf M., Eissele R., Schäfer M.K., Eiden L.E., Arnold R., Pauser U., et al. Expression of the two isoforms of the vesicular monoamine transporter (VMAT1 and VMAT2) in the endocrine pancreas and pancreatic endocrine tumors. J Histochem Cytochem 2003, 51(8):1027-1040.
5. 11C]DTBZ. Nucl Med Biol 2006, 33(7):855-864.
6. Freeby M., Goland R., Ichise M., Maffei A., Leibel R., Harris P. VMAT2 quantitation by PET as a biomarker for beta-cell mass in health and disease. Diabetes Obes Metab 2008, 10(Suppl 4):98-108.
7. 11C-dihydrotetrabenazine PET of the pancreas in subjects with long-standing type 1 diabetes and in healthy controls. J Nucl Med 2009, 50(3):382-389. [Epub 2009 Feb 17].
8. Goswami R., Ponde D.E., Kung M.P., Hou C., Kilbourn M.R., Kung H.F. Fluoroalkyl derivatives of dihydrotetrabenazine as positron emission tomography imaging agents targeting vesicular monoamine transporters. Nucl Med Biol 2006, 33(6):685-694.
9. 18F]fluoroethyl bromide as a synthetic precursor. Appl Radiat Isot 2002, 57(3):335-342.
10. Lammertsma A.A., Hume S.P. Simplified reference tissue model for PET receptor studies. Neuroimage 1996, 4(3 Pt 1):153-158.
11. 3H]dihydrotetrabenazine, a new in vitro monoaminergic probe for human brain. J Neurochem 1988, 50(4):1131-1136.
12. 11C]acetate in normal physiology. Eur J Nucl Med Mol Imaging 2009, 36(9):1453-1459. [Epub 2009 Apr 22].
13. Kilbourn M.R., Hockley B., Lee L., Hou C., Goswami R., Ponde D.E., et al. Pharmacokinetics of [18F]fluoroalkyl derivatives of dihydrotetrabenazine in rat and monkey brain. Nucl Med Biol 2007, 34(3):233-237.